Digital SPR Growth Nicoya’s launch of the Digital SPR platform and Alto Automation Suite signals a strategic shift toward higher throughput, automated biosensor workflows. Sales opportunities exist in offering scalable instrumentation, upgraded assay capabilities, and integration with automated sampling to pharma and biotech labs seeking faster drug discovery pipelines.

AAV and Carriers The introduction of AAVX and AAV9 Capture Kits indicates a focus on gene therapy research. Potential upsell opportunities include complementary capture solutions, assay kits, and end-to-end workflows that accelerate AAV-based therapeutic development and characterization for biotech customers advancing gene therapies.

Strategic Acquisitions Acquisition of Applied Photophysics expands capabilities in instrumentation and optics. This presents cross-sell potential for integrated biosensor solutions, bundled offerings, and service contracts that leverage broader hardware platforms for customers requiring diverse biophysics measurement tools.

Automation Partnerships Recent Labman Automation integration suggests demand for automated, end-to-end molecular analysis pipelines with real-time yield data. Opportunities exist in co-selling automation modules, software interfaces, and professional services to deliver turnkey, programmable SPR workflows to biopharma and contract research organizations.

Accessible Innovation Nicoya’s emphasis on affordability and ease of use positions them well for smaller biotech startups and academic labs. Sales focus could target entry-level SPR customers with scalable starter kits, training, and financing options to drive adoption of Alto platforms and expand market share in SMB segments.